ReviewThe Journal of international medical research2022
Antacids revisited: review on contemporary facts and relevance for self-management.
Review in The Journal of international medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Exploring the gut-exercise link: A systematic review of gastrointestinal disorders in physical activity.World journal of gastroenterology · 2025Pooled it
- Prospective uncontrolled clinical study shows rapid and long lasting relief of heartburn and acid related gastric discomfort with Refluthin.Scientific reports · 2025Trial
- Evaluation of Aluminum and Magnesium Absorption Following the Oral Administration of an Antacid Suspension Containing Magaldrate in Healthy Women Under Fed Conditions.Advances in therapy · 2024Trial
- Preoperative fasting guidelines: A narrative review.European journal of anaesthesiology and intensive care · 2026Review
- Metabolic engineering ofbioRxiv : the preprint server for biology · 2026Article
- Polymer/Titania Composites for the Remediation of Water from Pharmaceuticals: A Review.ACS omega · 2026Review
- Preclinical Studies on Plant Based-Antacid Formulations as New Therapies for Gastro-Oesophageal Reflux Disease.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Self-Management of Reflux-Like Symptoms: A Patient-Centered Decision-Making Approach.Digestive diseases (Basel, Switzerland) · 2026Review
- Empowering Pharmacists in Heartburn Management: Practical Insights for OTC Treatment and Self-Care.Pharmacy (Basel, Switzerland) · 2025Review
- In Vitro Evaluation of Drug-Drug Interaction Between Gliclazide and Antacids at the Absorption Level.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Acid-Neutralizing Omeprazole Formulation for Rapid Release and Absorption.Pharmaceutics · 2025Article
- Effect of antacid gastric syrups on surface properties of dental restorative materials: an in vitro analysis of roughness and microhardness.BMC oral health · 2025Article
- Gastroesophageal reflux disease increases predisposition to severe COVID-19: Insights from integrated Mendelian randomization and genetic analysis.Annals of human genetics · 2025Article
- Effects of famotidine use during pregnancy: an observational cohort study.Journal of pharmaceutical health care and sciences · 2024Article
- A combination of carbonates and Opuntia ficus-indica extract protects esophageal cells against simulated acidic and non-acidic reflux in vitro.Scientific reports · 2024Article
- Functionalized Calcium Carbonate-Based Microparticles as a Versatile Tool for Targeted Drug Delivery and Cancer Treatment.Pharmaceutics · 2024Review
- Chemoprofiling and medicinal potential of underutilized leaves of Cyperus scariosus.Scientific reports · 2024Article
- Overlap Between Gastroesophageal Reflux Disease and Functional Constipation and Associated Risk Factors Among the General Population in Saudi Arabia.International journal of general medicine · 2024Article
- New Perspectives in Endoscopic Treatment of Gastroesophageal Reflux Disease.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heartburn and acid regurgitation are the typical symptoms of gastroesophageal reflux. Despite the availability of several treatment options, antacids remain the mainstay treatment for gastroesophageal reflux-related symptoms based on their efficacy, safety, and over-the-counter availability. Antacids are generally recommended for adults and children at least 12 years old, and the FDA recommends antacids as the first-line treatment for heartburn in pregnancy. This narrative review summarizes the mechanism, features, and limitations related to different antacid ingredients and techniques available to study the acid neutralization and buffering capacity of antacid formulations. Using supporting clinical evidence for different antacid ingredients, it also discusses the importance of antacids as OTC medicines and first-line therapies for heartburn, particularly in the era of the COVID-19 pandemic, in which reliance on self-care has increased. The review will also assist pharmacists and other healthcare professionals in helping individuals with heartburn to make informed self-care decisions and educating them to ensure that antacids are used in an optimal, safe, and effective manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.